Neoplasms
Conditions
Interventions
It is a non-randomized, non-blinded, single-arm clinical trial. The study will include 20 older adults of both sexes diagnosed with cancer and receiving exclusive palliative care, hospitalized in the
Sponsors
Fundação Doutor Amaral Carvalho
Fundação Doutor Amaral Carvalho
Faculdade de Filosofia e Ciências/Universidade Estadual Paulista-UNESP
Eligibility
Age
60 Years to No maximum
Inclusion criteria
Inclusion criteria: Patients aged 60 or older with a diagnosis requiring exclusive Palliative Care, meaning those who will no longer receive any invasive or life-prolonging interventions; Patients with intact neurological function who are able to respond to commands and answer requested questionnaires; Patients who score between 1, 2, or 3 on the ECOG scale (where 1 – presents symptoms of the disease but is ambulatory and leads a normal day; 2 – Out of bed more than 50% of the time; and 3 – In bed more than 50% of the time) and score between 30% (Very disabled; requires hospitalization and active supportive treatment) and 70% (Able to care for oneself; unable to carry out normal activities or perform active work) on the Karnofsky Scale (performs transfers to a chair) to 7 (static gait with or without assistance); Patients with a score of 3 (performs transfers to a chair) to 7 (static gait with or without assistance) on the ICU Mobility Scale; Patients with a score on the Visual Analogue Scale. (EVA) from 3 (mild moderate pain) to 7 (intense moderate pain); Patients who report a score of 0 to 7 on the Borg Scale; 8. Patients who remain hospitalized for at least 7 days.
Exclusion criteria
Exclusion criteria: Patients who remain hospitalized for less than 7 days; Patients who develop a need for palliative sedation during the evaluation, intervention, or re-evaluation period; Medical advice for absolute bed rest; Intense ventilatory discomfort that makes it impossible to carry out the exercise program; 5. Death during the 7-day period in which the evaluation and intervention will be carried out.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Expected Outcome 1: Pain improvement is expected with the proposed treatment, verified using the Visual Analog Scale (VAS), based on a variation of at least 1.2 centimeters.;Outcome Found 1: Significant improvement in pain was found, as assessed by the Visual Analogue Scale (VAS), with a variation of 3.55 cm when comparing pre- and post-intervention.;Expected Outcome 2: Improvement in pain catastrophizing is expected using the Pain Catastrophic Thinking Scale (B-PCS), with a variation of at least 7.73 points between pre- and post-treatment.;Outcome Found 2: An improvement in pain catastrophizing was observed, with a change of 7.73 points when comparing pre- and post-treatment.;Expected Outcome 3: Improved functionality is expected with the proposed treatment, verified using the Intensive Care Unit Mobility (IMS) scale, based on a variation of at least 1 to 2 points.;Outcome Found 3: A clinically important improvement of 1.1 points in functionality was observed when comparing pre- and post-treatment.;Expected Outcome 4: Improvement in depression is expected with the proposed treatment, verified using the Geriatric Depression Scale (GDS-15), based on the finding of a change in the diagnostic category.;Outcome Finding 4: No clinical improvement in depression as assessed by the Geriatric Depression Scale (GDS-15) was observed when comparing pre- and post-treatment.;Expected Outcome 5: Improvement in the functional capacity domain is expected with the proposed treatment, assessed using the Medical Outcomes Study 36-item Short-Form Health Survey (SF-36), with a clinically important change of 8 to 10 points.;Outcome Found 5: A clinically significant improvement was observed in the functional capacity domain with the proposed treatment, as assessed by the Medical Outcomes Study 36-item Short-Form Health Survey (SF-36), with a change of 8.75 points.;Expected Outcome 6: Improvement in the physical aspects domain is expected with the proposed treatment, as assessed using the M | — |
Secondary
| Measure | Time frame |
|---|---|
| Expected Outcome 13: An improvement in the perception of effort is expected with the proposed treatment, as assessed using the Borg scale, with a clinically significant change of 1 point.;Outcome Finding 13: A clinically significant improvement was observed in the perception of effort in response to the proposed treatment, as assessed using the Borg scale, with a change of 2.05 points. | — |
Countries
BR
Contacts
Public ContactAlitéia Rodrigues
Fundação Doutor Amaral Carvalho
Outcome results
None listed